2012.04.30 Weekly Broadcast Email
The following updates were updates made to the CCCWFU CCOP Research Base website for the week of April 30, 2012.
97609 Amendment 4:
(Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity)
Amendment 4 documents have been posted to the website. This amendment includes protocol, consent and appendix changes.
Please note that Amendment 3 was an administrative amendment for WFU only. It was a personnel amendment adding WFU staff to the WFU eIRB system. No changes were made to any study documents in Amendment 3.
The non-Hispanic white accrual has reached 400 . Enrollment for this arm of the study has closed for additional participants. All other arms of the study are still available for accrual.
The following minority accruals are available: African American- 163, Hispanic/Latino- 190, Asian or Pacific Islander- 98, and American Indian or Alaska Native- 100. Thank you for your participation in this study.
During the month of April, 147 patients were accrued to CCCWFU CCOP Research Base trials. Congratulations to Northern Indiana Cancer Research, Wichita CCOP, and CTSU for accruing the most patients. See the Research Base website spotlight section for further information.
There were no adverse events received during the month of April.
(Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study)
Since 144 accruals remain, each site staff certified at the annual meeting that have not accrued a patient by April 22, 2012 will need to be recertified. Please send an audio tape containing a recording of you administering the 15 minute smoking cessation counseling. You can interview a coworker or family member, but not a patient. Sites can be recertified by sending an audio tape to the CCCWFU CCOP Research Base Protocol Information Office. (2000 W. 1st Street Suite 401, Winston-Salem, NC 27104)
(A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy)
Announcement from study PI:
As a reminder, our dose finding study of ArginMax for prostate cancer survivors treated with radiotherapy remains open for accrual. To date, we have accrued 90 + patients of a planned 140 averaging nearly 6 patients per month. We appreciate the robust accrual to date and overall support of this study. During the past months, we have noticed a slight dip in accrual. We encourage all sites to continue either their excellent accrual or consider opening this study. With your continued robust support, we are likely to finish this study in about 1 more year. If there are questions regarding accrual please do not hesitate to contact me or the study team.
James J. Urbanic, M.D.